Best of · compounded

Compounded GLP-1 providers, and what you are actually buying

The cheapest tier of this market, and the one that needs the most reading. Here is what each compounded service publishes — including the ones that admit on their own sales pages that the product is not FDA-reviewed.

Updated 2026-08-1415 sources

What compounded means, and where the rules are heading

Compounded GLP-1s are not FDA-approved products. Several of the services selling them say so on their own sales pages: Alloy states that “unlike FDA-approved drugs, compounded medications are not reviewed by the FDA for safety, effectiveness, or quality,” and Noom draws the sharper distinction — its product is “produced in an FDA-registered facility but has not been reviewed by the FDA for safety, efficacy, or quality.” A registered facility is not a reviewed medicine.

This tier is now under active enforcement. FDA announced 30 warning letters to telehealth companies in March 2026 and a further 25 in June, over false or misleading marketing of compounded GLP-1 products — including claiming or implying FDA approval, and describing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed,” which is an authorisation the agency does not grant. Five providers reviewed on this site are named recipients; their reviews say so at the top.

The larger development is structural, and it is worth quoting exactly. In a notice published on 1 May 2026 (91 FR 23431, Docket FDA-2018-N-3240), FDA said it “proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide.” That list is the set of substances for which FDA has found “a clinical need for outsourcing facilities to use in compounding”. Leaving all three off it would remove the legal basis for 503B outsourcing facilities to compound them in bulk — which is most of the cheap tier on this site.

It is a proposal, not a rule, and it is not settled. FDA extended the comment period on 26 June 2026, moving the deadline to 30 July. Nothing has been finalised as of this update. But anyone signing a twelve-month prepaid compounded plan should understand that the supply may not be lawful for the length of the plan, and should ask the provider what happens to the balance if it is not.

We could not retrieve fda.gov directly during this research, so the warning-letter counts are cited from the search index. The Federal Register notices above are quoted from the Federal Register’s own API.

Read the total, not the headline

Every compounded service in this research advertises a medication price and charges a separate membership on top. Alloy’s “$70” is $169 once the mandatory $99 membership is added. Ivím’s “$149” is $224 with its $74.99 membership. Brello’s “$166/month” is a $499 charge taken today and repeated every 11 weeks — four times a year, not three.

01Lowest verified total
Mochi Health
About $139/month all-in for compounded semaglutide and $169 for tirzepatide, with unlimited physician and care-team access included and cancel-anytime terms. It also offers brand-name Zepbound, so there is a route off compounded without changing service.
Full review
02Best clinician continuity
Alloy Weight Care
$169/month all-in for compounded semaglutide, $199 for tirzepatide. Membership buys unlimited messaging with the prescribing physician, dose adjustments and side-effect management — genuinely more clinical contact than the price suggests. Not available in AL, AR, CA, NV, LA, MS or DC.
Full review
03Best for HSA/FSA payers
Ivím Health
$224/month all-in, and the only compounded service here to confirm outright that an HSA or FSA card works. Also states plainly that compounded semaglutide is not covered by insurance.
Full review
04Clearest exit terms
Brello Health
Publishes actual refund mechanics — cancel anytime, $50 professional services fee retained after provider review. Everything is bundled into one charge including syringes and instructions.
Full review
05Most price options
Lemonaid Health
Compounded tirzepatide at $299/$249/$229 per month across monthly, 3-month and 6-month plans, microdoses at $199, plus a brand-name route in the same account. $49/month membership on top of all of it.
Full review

Compounded services compared

Compounded GLP-1 providers on verified terms
Provider	Total entry	Molecules	Refunds	Availability
AgelessRx	$99/mo	Microdose semaglutide, tirzepatide	Not stated	Cancel before next shipment
Noom	$179/mo	Microdose semaglutide, tirzepatide	Not stated	Cancel anytime; HSA/FSA
Mochi Health	$139/mo	Semaglutide, tirzepatide, Zepbound	Not stated	Not stated
Alloy	$169/mo	Semaglutide, tirzepatide	Not stated	Not in AL, AR, CA, NV, LA, MS, DC
Brello Health	$499 per 3 months	Tirzepatide + B6	Minus $50 fee after provider review	Not stated
Ivím Health	$224/mo	Semaglutide	Not stated	Not stated
Lemonaid	$248/mo microdose	Semaglutide, tirzepatide	Policy linked, not on page	Not stated

Total entry includes any mandatory membership. Sesame is excluded from this table: it states compounded semaglutide is not currently available through its platform.

Questions worth asking any compounded service

Which pharmacy compounds it, and is it a 503A or 503B facility?
Is the active ingredient semaglutide base, or a salt form such as semaglutide sodium or acetate?
What concentration is the vial, and how is the dose measured — units or millilitres?
What is the total monthly charge including membership, and when does it renew?
What happens to the remaining balance if you stop partway through a prepaid block?

The dosing question is not academic. FDA has published an alert about dosing errors with compounded semaglutide, describing adverse event reports “some requiring hospitalization” that may relate to overdoses. A vial and a syringe put the arithmetic on the patient in a way a pre-filled pen does not.

Questions

Is compounded semaglutide legal?

Compounding is a regulated activity, but compounded GLP-1s are not FDA-approved products, and FDA has stated its enforcement posture depends on shortage conditions. It has also issued warning letters to compounders over misbranded semaglutide and tirzepatide products. We could not retrieve fda.gov directly during this research, so read the FDA pages linked in our sources rather than relying on our summary.

Why is compounded so much cheaper?

It is not the approved product and has not been through the same review. That is the entire basis of the price difference, and it is the trade you are making.

Which compounded provider is cheapest in total?

Mochi Health, at about $139/month for compounded semaglutide once its $79 membership is included. Alloy is next at $169, and is the better choice if prescriber continuity matters more than the $30 — provided you are not in one of the seven jurisdictions it excludes.

Sources

Everything on this page traces to one of the links below, retrieved on the date shown. Prices and programme terms in this market change without notice — confirm against the provider before you buy.

01Mochi Health — membership pricing, medications, FDA caveat, cancellationretrieved 2026-08-14
02Alloy — compounded semaglutide pricing and membershipretrieved 2026-08-14
03Alloy — compounded tirzepatide, shipping and FDA caveatretrieved 2026-08-14
04Ivím Health — compounded semaglutide pricing, HSA/FSA and insuranceretrieved 2026-08-14
05Brello Health — compounded tirzepatide billing and refund termsretrieved 2026-08-14
06Lemonaid Health — weight loss pricing and membershipretrieved 2026-08-14
07Sesame — semaglutide pricing, labs and compounded positionretrieved 2026-08-14
08FDA — “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (cited from search index; fda.gov refused direct retrieval)retrieved 2026-08-14
09FDA — “FDA alerts health care providers, compounders and patients of dosing errors” (cited from search index)retrieved 2026-08-14
10FDA — “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize” (cited from search index)retrieved 2026-08-14
11FDA — “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1 Drugs”, 3 March 2026 (cited from the search index)retrieved 2026-08-16
12FDA — “Telehealth Companies: What to Know When Promoting Compounded Drugs” (cited from the search index)retrieved 2026-08-16
13FDA — “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks List”, April 2026 (cited from the search index)retrieved 2026-08-16
14Federal Register — “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B”, notice 2026-08552, published 1 May 2026 (91 FR 23431), Docket FDA-2018-N-3240retrieved 2026-08-16
15Federal Register — same notice, Extension of Comment Period, notice 2026-12937, published 26 June 2026; comments due 30 July 2026retrieved 2026-08-16

Read the total, not the headline

Mochi Health

Alloy Weight Care

Ivím Health

Brello Health

Lemonaid Health

Compounded services compared

Questions worth asking any compounded service

Questions

Read next

Sources